Natco Pharma announced that a US District Court has issued a decision in favour of Pharmacyclics (a subsidiary of AbbVie), the brand owner of Imbruvica in a PIV litigation involving the product.

NATCO and its marketing partner in the US for the product, Alvogen Pine Brook LLC, USA, shall review the judgement and evaluate all options to appeal the judgement. ``We believe that we have a strong case and will continue to defend vigorously,’’ the company said in a statement.

In 2018 NATCO and Alvogen, had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product.